177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With Prostate Cancer

Prior treatment

• Prior cytotoxic chemotherapy and/or radiation therapy within 4 weeks of treatment
• Prior radiation therapy encompassing \>25% of skeleton (see Appendix C)
• Prior treatment with 89Strontium or 153Samarium containing compounds (e.g. Metastron®, Quadramet®)
• Prior investigational therapy (medications or devices) within 4 weeks of treatment. Furthermore, other investigational therapy is not permitted during the treatment phase.
• Prior use of ketoconazole for the purposes of prostate cancer therapy for greater than 1 month
• Adrenal hormone inhibitors (other than ketoconazole) within 4 weeks prior to study enrollment
• Patients on corticosteroids prior to enrollment must have either discontinued and shown biochemical progression or have biochemical progression on a stable dose

Other illness

• Active serious infection
• Active angina pectoris or NY Heart Association Class III-IV
• History of deep vein thrombosis and/or pulmonary embolus within 1 month of study entry
• Other serious illness(es) involving the cardiac, respiratory, CNS, renal, hepatic or hematological organ systems which might preclude completion of this study or interfere with determination of causality of any adverse effects experienced in this study
• Known history of HIV. The effects of J591 are unknown in this population. Furthermore, ketoconazole has many well-described drug-drug interactions which could affect antiviral therapy. If necessary, this population will be studied separately.
• Currently active other malignancy other than non-melanoma skin cancer. Patients are considered not to have "currently active" malignancy if they have completed any necessary therapy and are considered by their physician to be at less than 30% risk of relapse.
  • \- Known history of known myelodysplastic syndrome

Lab values

• Use of red blood cell or platelet transfusions within 4 weeks of treatment
• Platelet count \<150,000/mm3 or known primary qualitative platelet disorder
• Absolute neutrophil count (ANC) \<2,000/mm3
• Hematocrit \<30 percent and Hemoglobin \< 10 g/dL
• Abnormal coagulation profile (PT or INR, PTT \> 1.3x ULN) unless on therapeutic anticoagulation - see concomitant meds section
• Serum creatinine \>2.5 mg/dL
• AST (SGOT) \>2x ULN
• Bilirubin (total) \>1.5x ULN; subjects with Gilbert's syndrome will be allowed if direct bilirubin is within institutional normal limits

Other

• Use of hematopoietic growth factors within 4 weeks of treatment
• ECOG Performance Status \> 2
• Life expectancy \<12 months
• Finasteride (Propecia® or Proscar®) or dutasteride (Avodart®) within 4 weeks of enrollment

• Histologically or cytologically confirmed adenocarcinoma of the prostate previously treated with surgery and/or radiotherapy.
• Biochemical progression (rising PSA) after medical or surgical castration
• High risk of systemic progression defined as:
  • Rising PSA as defined above and either:
  • Absolute PSA \> 20 ng/mL AND/OR
  • PSA doubling time \< 8 months
• No evidence of local recurrence or distant metastases
• Age \>18 years.
• Serum testosterone \< 50 ng/ml
• Patients capable of fathering children must agree to use an effective method of contraception for the duration of the trial.
• Subjects on bisphosphonate therapy must be on a stable dose and must have started therapy \> 4 weeks prior to protocol therapy.
• Ability to understand and the willingness to sign a written informed consent document.